CLAIMS

1. A composition comprising mesenchymal lineage precursor or stem cells (MLPSCs), in which the MLPSCs have been culture expanded, cryopreserved and thawed, in which MLPSCs of the population were culture expanded from a cell population that was enriched for STRO-1+ cells from a cell population comprising STRO-1+ cells, in which the MLPSCs inhibit IL-2Rα expression by ≥ 65%, in which inhibition of expression of IL-2Rα is measured by co-incubation of the MLPSCs and the sample of PBMCs comprising activated T cells at a ratio of 1 MLPSC:5 PBMC or less, in which the level of inhibition of IL-2Rα expression by the MLPSCs is determined in the activated T cells.

2. A composition according to Claim 1, in which the ratio is:

1 MLPSC:10 PBMC, or less;

1 MLPSC:50 PBMC, or less; or

1 MLPSC:100 PBMC, or less.

3. A composition according to Claim 1 or 2, in which the MLPSCs inhibit IL-2Rα expression by ≥ 70%.

4. A composition according to Claim 1, 2 or 3, in which the MLPSCs inhibit IL-2Rα expression by ≥ 80%.

5. A composition according to any preceding claim, in which the MLPSCs are culture expanded by a method comprising:

culturing a population of MPCs or MSCs in a culture medium comprising recombinant trypsin;

culturing the cells in a cell factory with one or more attached air filters;concentrating and/or washing the cells with tangential flow filtration (TFF); and

passing the cells through a dual screen mesh filter, thereby reducing visible particulates and/or cell aggregates.

6. A composition according to any preceding claim, in which the cells in the composition consist of MSCs.

7. Use of a composition according to any preceding claim in the manufacture of a medicament for alleviating the development of, or treating graft versus host disease (GvHD) in a subject.

8. Use according to Claim 7, in which the composition comprises a dose of less than 3 x 10^6 cells/kg.

9. Use according to Claim 8, in which the composition comprises a dose of about 2 x 10^6 cells/kg.

10. Use according to Claim 7, 8 or 9, in which the composition is formulated for administration as a single dose or as a divided dose(s).

11. Use according to any of Claims 7 to 10, in which:

(i) the subject has a malignant or genetic disorder of the blood; or

(ii) the subject has received, is receiving or is about to receive a donor graft comprising hematopoietic cells.

12. Use according to any of Claims 7 to 11, in which the subject is refractory to steroid therapy.